Related Experiment Videos
Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting
1Multiple Sclerosis Research and Immunology Unit, Dr. L. Willems Instituut, Diepenbeek, Belgium.
Cytotechnology
|January 1, 1994
Summary
T cell vaccination effectively depleted myelin basic protein-reactive T cells in multiple sclerosis (MS) patients. This approach shows promise for treating MS and other autoimmune diseases by targeting autoreactive T cells.
Area of Science:
- Neuroimmunology
- Autoimmunity
Background:
- Autoreactive T cells targeting myelin proteins, like myelin basic protein (MBP), are implicated in multiple sclerosis (MS) pathogenesis.
- These MBP-reactive T cells are activated, expanded, and accumulate in the brain in MS patients, indicating a pathological role.
Purpose of the Study:
- To review evidence on the pathological relevance of MBP-reactive T cells in MS.
- To present findings from a clinical trial using T cell vaccination in MS patients.
- To investigate the in vivo nature of clonotypic responses and their efficacy in depleting circulating MBP-reactive T cells.
Main Methods:
- Review of recent evidence on MBP-reactive T cells in MS.
- Clinical trial involving vaccination of MS patients with inactivated autologous MBP-reactive T cell clones.
- Assessment of clonotypic responses and depletion of MBP-reactive T cells.
Main Results:
- Demonstrated successful depletion of MBP-reactive T cells through T cell vaccination in MS patients.
- Provided insights into the clinical application of T cell vaccination in humans.
Conclusions:
- T cell vaccination is a viable strategy for depleting pathogenic MBP-reactive T cells in MS.
- This therapeutic approach offers potential for treating MS and other autoimmune conditions.